CASI制药 CASI 深 沪
已收盘 02-06 16:00:00 美东时间
0.9247
-0.025
-2.66%
华盛通- 最 高0.95
- 今 开0.9237
- 成交量 1.74万股
- 最 低 0.905
- 昨 收 0.95
- 总市值 1900.80万
- 52周最高 3.09
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 0.75
- 委 比 -53.54%
- 总股本 2055.59万
- 历史最高 88.92
- 量 比 0.82
- 振 幅 4.74%
- 历史最低 0.75
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CASI Pharmaceuticals Gets China National Medical Products Administration's Approval To Start Phase1/2 Clinical Study For CID-103 In Adults With Chronic Active Renal Allograft Antibody-Mediated Rejection
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38 monoclonal antibody, for patients with organ transplant rejection and
01-15 22:05
CASI Pharmaceuticals Granted Extension Through February 17, 2026 To Regain Nasdaq Compliance
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection
2025-12-24 05:06
CASI Pharmaceuticals Receives Nasdaq Delisting Notification
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection
2025-11-11 05:19
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
2025-09-27 01:05
CASI Pharmaceuticals Strengthens Board with Industry Veteran James Huang
CASI Pharmaceuticals ( ($CASI) ) has provided an update. On September 26, 2025,...
2025-09-26 21:47
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and maintains $4 price target.
2025-09-03 19:00
CASI Pharmaceuticals Faces Setback with FOLOTYN® License Expiration in China
The latest announcement is out from CASI Pharmaceuticals ( ($CASI) ). CASI Phar...
2025-08-28 04:55
CASI Pharmaceuticals shares are trading higher after the company announced FDA clearance for CID-103.
CASI Pharmaceuticals shares are trading higher after the company announced FDA ...
2025-08-04 23:39
CASI Pharmaceuticals Appoints David Cory as CEO to Drive CID-103 Program
CASI Pharmaceuticals ( ($CASI) ) has issued an announcement. On July 21, 2025, ...
2025-07-22 18:28
CASI Pharmaceuticals announces CEO appointment
CASI Pharmaceuticals (NASDAQ:CASI) has named David Cory as its new chief executive officer and board member. Wei-Wu He, Ph.D., will step down as CEO and transition to the role of executive chairman of...
2025-07-22 04:21
